Ipatasertib
- Generic Name
- Ipatasertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32ClN5O2
- CAS Number
- 1001264-89-6
- Unique Ingredient Identifier
- 524Y3IB4HQ
- Background
Ipatasertib has been used in trials studying the treatment of Cancer, Neoplasms, Solid Cancers, Breast Cancer, and Gastric Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT05862285
- Locations
- 🇧🇪
GHdC Site Notre Dame, Charleroi, Belgium
🇫🇷Institut de Cancérologie de Bourgogne, Dijon, France
🇫🇷Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque, Montpellier, France
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Conditions
- Metastatic HER2-Negative Breast CarcinomaLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Malignant Female Reproductive System NeoplasmRecurrent Ovarian CarcinomaUnresectable HER2-Negative Breast CarcinomaUnresectable Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
- Interventions
- Procedure: BiopsyDrug: AlpelisibDrug: BinimetinibProcedure: Bone Marrow AspirationProcedure: Biospecimen CollectionProcedure: Bone ScanDrug: IpatasertibProcedure: Computed TomographyProcedure: EchocardiographyDrug: Nilotinib Hydrochloride MonohydrateBiological: PanitumumabProcedure: Magnetic Resonance ImagingDrug: PaclitaxelDrug: SotorasibDrug: OlaparibDrug: FluorouracilDrug: Neratinib MaleateProcedure: Mutation Carrier ScreeningDrug: LeucovorinDrug: FulvestrantDrug: Selumetinib SulfateProcedure: Positron Emission TomographyDrug: PalbociclibProcedure: Multigated Acquisition ScanDrug: Oxaliplatin
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2900
- Registration Number
- NCT05564377
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
- Conditions
- FIGO Grade 1 Endometrial Endometrioid AdenocarcinomaFIGO Grade 2 Endometrial Endometrioid AdenocarcinomaMetastatic Endometrial Endometrioid AdenocarcinomaRecurrent Endometrial Endometrioid Adenocarcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyDrug: IpatasertibProcedure: Magnetic Resonance ImagingDrug: Megestrol Acetate
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 96
- Registration Number
- NCT05538897
- Locations
- 🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.